ESR1 and breast carcinoma: Even though a role of SNHG6 in cancer radio-resistance (13) as well as chemoresistance (14), particularly resistance against cisplatin (15) and paclitaxel (16) has been described, there is no report on it’s possible role in acquired tamoxifen resistance of ER-positive breast cancers, prompting us to plan this study.